Loading filters...
Publications per Year (803 total)
6
1990
9
·
5
·
6
·
3
·
12
1995
8
·
12
·
7
·
18
·
20
2000
12
·
17
·
16
·
19
·
22
2005
30
·
28
·
25
·
25
·
35
2010
23
·
37
·
39
·
27
·
24
2015
17
·
25
·
32
·
26
·
35
2020
35
·
43
·
32
·
28
·
32
2025
13
·
Loaded
Click to load
50 / 803 papers loaded(scroll for more)
20264 papers
GeneralAll Stages2026
Longitudinal Profiling of Cervical Cancers Reveals Therapy-Induced Vulnerabilities Beyond the Checkpoint.
Klopp AH et al. Cancer Res. 2026
GeneralAll Stages2026
Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer.
Sandoval TA et al. Cancer Res. 2026
GeneralAll Stages2026
A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.
Ryu SY et al. ESMO Open. 2026
GeneralAll Stages2026
Refinement in radiotherapy treatment for locally advanced cervical cancer: a historic perspective.
Caicedo-Martínez M et al. Int J Gynecol Cancer. 2026
202524 papers
Generaladvanced2025
Patterns of pembrolizumab use for recurrent cervical cancer.
Huang Y et al. Int J Gynecol Cancer. 2025
GeneralEarly (I-IIA)2025
Evaluation of toxicity after radical hysterectomy or trachelectomy and post-operative pelvic intensity-modulated radiation therapy with concurrent chemotherapy for cervical cancer.
Manning-Geist BL et al. Int J Gynecol Cancer. 2025
Antiangiogenicadvanced2025
Circulating human papillomavirus DNA sequencing as a biomarker of response in advanced cervical cancer.
Collier E et al. Int J Gynecol Cancer. 2025
GeneralAll Stages2025
Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study.
Baek JY et al. J Gynecol Oncol. 2025
GeneralAll Stages2025
The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
Kim YJ et al. Gynecol Oncol. 2025
Generaladvanced2025
Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.
Seo A et al. Clin Cancer Res. 2025
AntiangiogenicAll Stages2025
Revision of quality indicators for cervical cancer and trend analysis of existing indicators in Japan.
Kakuwa T et al. J Gynecol Oncol. 2025
Generaladvanced2025
Nimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial.
Wei S et al. J Gynecol Oncol. 2025
Antiangiogenicadvanced2025
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.
Takekuma M et al. J Gynecol Oncol. 2025
Antiangiogenicadvanced2025
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.
Kim YM et al. J Gynecol Oncol. 2025
GeneralAll Stages2025
ARTIA-Cervix: a prospective trial of adaptive radiation therapy for cervical cancer.
Mayadev JS et al. Int J Gynecol Cancer. 2025
GeneralEarly (I-IIA)2025
Chemo-conization in Early-sTage cERvical caNcer >2 cm scheduled for fertilItY-sparing approach: an analysis of the ETERNITY project.
Bogani G et al. Int J Gynecol Cancer. 2025
GeneralAll Stages2025
Intensified radiochemotherapy with cisplatin and gemcitabine for cervical cancer in the modern era: a retrospective cohort study.
Riggenbach E et al. J Gynecol Oncol. 2025
Immunotherapyadvanced2025
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Lorusso D et al. Gynecol Oncol. 2025
GeneralAll Stages2025
Follow-up strategies for patients with cervical cancer who achieved complete response after definitive chemoradiotherapy.
Kim YJ et al. Int J Gynecol Cancer. 2025
GeneralEarly (I-IIA)2025
Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.
Hardie AN et al. Eur J Cancer. 2025
GeneralEarly (I-IIA)2025
Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer.
Agustí N et al. JAMA Oncol. 2025
Generaladvanced2025
Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.
MacDuffie E et al. Gynecol Oncol. 2025
GeneralEarly (I-IIA)2025
Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).
Chase DM et al. Gynecol Oncol. 2025
Generaladvanced2025
Efficacy and safety of cisplatin combined with paclitaxel concurrent radiotherapy in patients with locally advanced cervical squamous cell carcinoma.
Feng T et al. J Gynecol Oncol. 2025
GeneralAll Stages2025
Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study.
Hu L et al. J Gynecol Oncol. 2025
GeneralAll Stages2025
Addition of chemotherapy to radiation is associated with improved survival in older patients with cervical cancer: a Surveillance, Epidemiology, and End Results database analysis.
Leetanaporn K et al. Int J Gynecol Cancer. 2025
GeneralEarly (I-IIA)2025
Clinical outcomes of external radiotherapy boost versus no boost to radiologically positive lymph nodes in FIGO stage IIIC cervical cancer.
Rishi KS et al. Int J Gynecol Cancer. 2025
Antiangiogenicadvanced2025
Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214).
Li C et al. J Gynecol Oncol. 2025
202422 papers
ImmunotherapyAll Stages2024
Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer.
Diggs A et al. Int J Gynecol Cancer. 2024
Immunotherapyadvanced2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Oaknin A et al. Lancet Oncol. 2024
GeneralAll Stages2024
Premature adoption of adjuvant chemotherapy for locally advanced cervical carcinoma before the OUTBACK trial: cautionary tale on outcomes.
Nasioudis D et al. Int J Gynecol Cancer. 2024
GeneralEarly (I-IIA)2024
Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer.
Matsuo K et al. Int J Gynecol Cancer. 2024
Generaladvanced2024
Intraepithelial tumor-infiltrating lymphocytes shape loco-regional PET/CT spread of locally advanced cervical cancer.
Del M et al. Int J Gynecol Cancer. 2024
GeneralAll Stages2024
Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial.
Cho WK et al. JAMA Oncol. 2024
Generaladvanced2024
Guideline concordant care for patients with locally advanced cervical cancer by disaggregated Asian American and Native Hawaiian/Pacific Islander groups: A National Cancer Database Analysis.
Lee SS et al. Gynecol Oncol. 2024
Generaladvanced2024
Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial).
Yun BS et al. J Gynecol Oncol. 2024
GeneralAll Stages2024
Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation.
Shi V et al. Int J Gynecol Cancer. 2024
Generaladvanced2024
RECIST 1.1 versus clinico-radiological response assessment for locally advanced cervical cancer: implications on interpreting survival outcomes of future trials.
Charnalia M et al. Int J Gynecol Cancer. 2024
Immunotherapyadvanced2024
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V et al. Eur J Cancer. 2024
GeneralEarly (I-IIA)2024
Accuracy of pre-operative tumor size assessment compared to final pathology and frequency of adjuvant treatment in patients with FIGO 2018 stage IB2 cervical cancer.
Pan TL et al. Int J Gynecol Cancer. 2024
GeneralEarly (I-IIA)2024
Para-aortic lymph node recurrence in surgically treated early-stage cervical cancer without para-aortic lymph node surgical staging.
Golia D'Augè T et al. Int J Gynecol Cancer. 2024
GeneralEarly (I-IIA)2024
The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
Ng ZY et al. Gynecol Oncol. 2024
Antiangiogenicadvanced2024
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
Oaknin A et al. Clin Cancer Res. 2024
GeneralAll Stages2024
Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
Chuk E et al. Gynecol Oncol. 2024
Antiangiogenicadvanced2024
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
Li G et al. Gynecol Oncol. 2024
Antiangiogenicadvanced2024
Cervical cancer: a new era.
Caruso G et al. Int J Gynecol Cancer. 2024
Antiangiogenicadvanced2024
QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial.
Fang C et al. J Gynecol Oncol. 2024
Antiangiogenicadvanced2024
Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer.
Walker CA et al. Gynecol Oncol. 2024
Generaladvanced2024
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group.
Akyildiz A et al. Int J Gynecol Cancer. 2024
Antiangiogenicadvanced2024
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study.
Lou H et al. Clin Cancer Res. 2024